

## Valerio Bronzo

Università degli Studi di Milano

# Bacterial biofilm

Bronzo V.<sup>1</sup>, Locatelli C.<sup>1</sup>, Scaccabarozzi L.<sup>1</sup>, Casula A.<sup>2</sup>, Rota N.<sup>1</sup>, Pollera C.<sup>2</sup>, Moroni P.<sup>1,3</sup>

<sup>1</sup>Università degli Studi di Milano, Department of Health, Animal Science and Food Safety; <sup>2</sup>Università degli Studi di Milano, Department of Veterinary Science and Public Health; <sup>3</sup>Department of Population Medicine and Diagnostic Sciences, Quality Milk Production Services, College of Veterinary Medicine, Cornell University.

### General features

Biofilms are a structured community of bacterial cells enclosed in a self-produced polymeric matrix and adherent to an inert or living surface (Costerton et al., 1999). This can constitute a protected niche that allows bacteria to grow and survive in a hostile environment, particularly in environments characterized by a continuous flow. When biofilms are formed in low shear environments, they are generally more sensitive to mechanical breakage. In addition to protection against physical and chemical environmental agents, the biofilm promotes extracellular catabolism and the concentration of nutrients on cell surface.

In most natural environments, microorganisms try to adhere to available surfaces. Hence, the free-swimming (planktonic) phase can be viewed as a bacterial dispersal from one surface to colonize another. Thus, the initial phase of biofilm formation involves two stages: the first one consists in attachment of cells to a surface, facilitated by cell wall associated adhesins, which are products of various genes (Mack, 1999). Attachment to native polymeric surfaces is increased in the presence of matrix proteins including fibronectin, and fibrinogen. Following initial attachment of cells to a surface, the primary cell aggregates produce exopolysaccharides to facilitate clumping. The second stage is characterized by cell multiplication and formation of a mature structure consisting of many layers of cells, connected each other by extracellular polysaccharides (Yarwood and Schlievert, 2003). Finally, in the process of maturation, many staphylococci generate a glycocalyx, a slime layer that further protects the biofilm bacteria. The chemical nature of these slime layers is still not entirely elucidated, but evidence suggests that it consists predominantly of hydrated polysaccharides.

The growth potential of any bacterial biofilm is limited by the availability of nutrients to the cells within the biofilm and distinct flow-through channels across the biofilm aim to maintain perfusion (Stoodley et al., 2002). Other factors that are known to control biofilm maturation include internal pH, oxygen perfusion, carbon source and osmolarity (Dunne, 2002). Biofilm lives a dynamic equilibrium and when it reaches a critical mass the outermost cell layer begins to shed planktonic organisms. These bacteria are free to escape the biofilm and to colonize other surfaces (Dunne, 2002). The formation



of biofilms is often involved in the pathogenesis of many human infections caused by various microorganisms such as staphylococci, streptococci, *Ps. aeruginosa*, *Haem. influenzae*, in many urinary infections caused by *E. coli*, as well as in infections in case of use of prostheses and implants (Hall-Stoodley et al., 2004).

### Action mechanisms

Biofilm production allows bacteria to resist to antibiotic therapy, ensures infection persistence and the resistance to host immunity.

Resistance to antimicrobial agents (e.g. antibiotics) of bacteria within biofilm seems to be related to several factors: a) increased difficulty of the antibiotic to penetrate through the extracellular matrix, b) a decrease in rate of cell division ( $\beta$ -lactam antibiotics are effective against Gram-positive bacteria in active multiplication), c) the presence of resistant phenotypes in a bacterial population genetically heterogeneous, d) greater resistance to phagocytosis (Costerton et al., 1999). Despite some studies have reported an unimpaired antimicrobial penetration (Anderl et al., 2003), to induce the production of beta-lactamases by bacteria established in the heart of a biofilm is necessary the exposure to a higher concentration of antibiotic than in bacteria in the peripheries of biofilm (Bagge et al., 2004). Biofilm penetration of positively charged aminoglycosides is retarded by binding to negatively charged matrices, such as alginate in *Pseudomonas aeruginosa* biofilms (Walters et al., 2003). Finally, biofilm from coagulase-negative staphylococci reduced the effect of glycopeptide antibiotics, even in planktonic bacterial cultures (König et al., 2001; Souli & Giamarellou, 1998).

Resistance to host immunity contribute to maintain persistent infections. Normally planktonic bacteria are able to stimulate the production of antibodies but these are not effective against bacteria into biofilm deeper layers and may cause immune complex damage to surrounding tissues (Cochrane et al., 1998). Even in non-immunosuppressed individuals, infections caused by biofilm-producing pathogens are rarely resolved by the host defense mechanisms (Khoury et al., 1992).

All these mechanisms allow several human and animal infections to become chronic. The specific mode of growth of biofilm through release of planktonic cells is particularly related to the capability to colonize new sites and perpetuate infections.

### *Staph. aureus* biofilm

*Staph. aureus* represents a major agent of contagious bovine mastitis and its ability to form biofilm suggests that it is a possible important virulence factor in the establishment of staphylococcal infection (Costerton et al. 1999).

The main constituent of the extracellular matrix, responsible for intercellular



*Staph. aureus* interactions, is the exopolysaccharides poly-N-acetyl- $\beta$ -1, 6 glucosamine (PNAG) synthesized by enzymes encoded from *icaADBC* operon. Some studies have found *icaADBC* operon, coding for the enzymes responsible for the biosynthesis of PNAG exopolysaccharides, in 94.36% (Cucarella et al., 2004) or in 100% (Vasudevan et al., 2003) strains of *Staph. aureus* isolated from bovine mastitis.

Besides this genetic trait, other studies have also shown a remarkable ability to produce biofilm *in vitro* by *Staph. aureus* isolated from cases of bovine mastitis (Vadusevan et al., 2003, Olivera et al., 2007).

The *in vivo* presence of the exopolysaccharides complex was also demonstrated indirectly by observing the production of specific antibodies against PNAG (Pérez et al., 2009) and SAAC (Slime Associated Antigenic Complex; Prenafeta et al., 2010) respectively in ewes and cows with experimentally induced *Staph. aureus* intramammary infections.

## Vaccination against *Staph. aureus* intramammary infections

The attention paid to prevent antimicrobial resistance, particularly in methicillin-resistant *Staph. aureus* (MRSA), and a general trend, in the future, to reduce the use of antibiotics in livestock (FDA, 2010), explain the effort to develop new effective vaccines against bacterial infections.

Especially in the regards of *Staph. aureus* intramammary infections, several studies were performed to find an effective vaccine in order to decrease the spread of infection among and within herds. The targets in vaccination against mastitis are to obtain reduced inflammation at the site of injection, high efficiency against disease, a cost-efficient bacterial inoculum and an immunological parameter that could help to predict the success of vaccination (Pérez et al., 2009).

First study about vaccination against whole bacterial cells surrounded by their own biofilm matrix containing PNAG conferred protection against *Staph. aureus* infection and mastitis in a challenge study in sheep. The protection level was related to the features of the immunizing strain (degree of biofilm formation and PNAG production) and consequently to the rate of antibodies to *Staph. aureus* PNAG. Whereas of it was independent of the adjuvant and capsular polysaccharide type of the challenge strain (Pérez et al., 2009).

Further study by Prenafeta et al. in cattle (2010) has point out the active role of specific antibodies against SAAC. The immunogenicity of SAAC was demonstrated when this component was administered associated with the *Staph. aureus* bacterin in dairy heifers. Cows immunized with a greater amount of SAAC associated with the *Staph. aureus* bacterin triggered the highest SAAC-specific antibody levels in serum after vaccination. In conclusion, this study reports the immunogenicity of SAAC in dairy cows when this component is embedded in a *Staph. aureus* bacterin of a strong biofilm-producing strain and candidate it as an effective target for vaccination (Prenafeta et al. 2010).

One of the benefit of using PNAG or SAAC, as antigenic component of the vaccine, is that no different serotypes have been highlighted of *Staph. aureus* in relation to the production of the two fractions mentioned above. Therefore, the antibodies induced by vaccination with these antigens give cross-protection against several strains of *Staph. aureus*.

## References

- Anderl J.N., Zahler J., Roe F., Stewart E.S., 2003. Role of nutrient limitation and stationary-phase existence in *Klebsiella pneumoniae* biofilm resistance to ampicillin and ciprofloxacin. *Antimicrob. Agents Chemother.* 47: 1251-1256.
- Bagge N., Hentzer M., Andersen J.B., Cloff O., Givskov M., Heiby N., 2004. Dynamics and spatial distribution of beta-lactamase expression in *Pseudomonas aeruginosa* biofilms. *Antimicrob. Agents Chemother.* 48: 1168-1174.
- Cochrane D.M., Brown M.R., Anwar H., Weller B.H., Lam K. and Costerton J.W., 1998. Antibody response to *Pseudomonas aeruginosa* surface protein antigens in a rat model of chronic lung infection. *J. Med. Microbiol.* 27: 255-261.
- Costerton J.W., Stewart P.S. and Greenberg E.B., 1999. Bacterial biofilms: a common cause of persistent infections. *Science.* 284: 1318-1322.
- Cucarella C., Tormo M.A., Úbeda C., Trotón M.P., Monzón M., Peris C., Amorosa B., Lasa I. and Penadés J.R., 2004. Role of biofilm-associated protein Bap in the pathogenesis of bovine *Staphylococcus aureus*. *Infect. Immun.* 72:2177-2185.
- Dunne W.M. Jr., 2002. Bacterial adhesion: seen any good biofilms lately? *Clinical Microbiology Reviews.* 15: 155-166.
- Food and Drugs Administration, U.S. Department of Health and Human Services, 2010, The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals, 1-26.
- Hall-Stoodley L., Costerton J.W. and Stoodley P., 2004. Bacterial biofilms: from the natural environment to infectious diseases. *Nature Reviews Microbiology.* 2: 95-108.
- König C., Schwank S., Blaser J., 2001. Factors compromising antibiotic activity against biofilms of *Staphylococcus epidermidis*. *Eur. J. Clin. Microbiol. Infect. Dis.* 20: 20-26.
- Khoury A.E., Lam K., Ellis B. and Costerton J.W., 1992. Prevention and control of bacterial infections associated with medical devices. *ASAIO J.* 38: M174-178.
- Mack D., 1999. Molecular mechanisms of *Staphylococcus epidermidis* biofilm formation. *J. Hosp. Infect.* 43 Suppl:S113-125. Review.
- Oliveira M., Nunes S.F., Carneiro C., Beziga R., Bernardo F. and Vilela C.L., 2007. Time course of biofilm formation by *Staphylococcus aureus* and *Staphylococcus epidermidis* mastitis isolates. *Vet. Microbiol.* 124:187-191.
- Pérez M.M., Prenafeta A., Valle J., Penadés J., Rota C., Solano C., Marco J., Grilló M.J., Lasa I., Irache J.M., Maira-Litran T., Jiménez-Barbero J., Costa L., Pier G.B., de Andrés D., Amorosa B., 2009. Protection from *Staphylococcus aureus* mastitis associated with poly-N-acetyl  $\beta$ -1,6 glucosamine specific antibody production using biofilm-embedded bacteria. *Vaccine.* 27, 2379-2386.
- Prenafeta A., March R., Foix A., Casals I. and Costa L.L., 2009. Study of the humoral immunological response after vaccination with a *Staphylococcus aureus* biofilm-embedded bacterin in dairy cows: possible role of the exopolysaccharide specific antibody production in the protection from *Staphylococcus aureus* induced mastitis. *Vet. Immun. Immunopathol.* 134:208-217.
- Souli M., Giannelliou H., 1998. Effects of slime produced by clinical isolates of coagulase negative staphylococci on activities of various antimicrobial agents. *Antimicrob. Agents Chemother.* 42: 939-941.
- Stoodley P., Cargo R., Rupp C.J., Wilson S. and Klapper I., 2002. Biofilm material properties as related to shear-induced deformation and detachment phenomena. *J. Ind. Microbiol. Biotechnol.* 29: 361-367.
- Vasudevan V., Nair M.K.M., Annamalai T. and Venkitanarayanan K.S., 2003. Phenotypic and genotypic characterization of bovine mastitis isolates of *Staphylococcus aureus* for biofilm formation. *Vet. Microbiol.* 92:179-185.
- Walters M.C. 3rd, Roe F., Bugnicourt A., Franklin M.J., Stewart E.S., 2003. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of *Pseudomonas aeruginosa* biofilms to ciprofloxacin and tobramycin. *Antimicrob. Agents Chemother.* 47: 317-323.
- Yarwood J.M., Schlievert B.M., 2003. Quorum sensing in *Staphylococcus* infections. *J. Clin. Invest.* 112: 1620-1625.